Anticancer Agent 141 (Compound AE), an antimycin alkaloid, exhibits inhibitory potential against HPV-infected cervical cancer. It impedes HeLa cell proliferation by arresting the cell cycle at the S phase and induces caspase-dependent apoptosis through mitochondrial disruption. This disruption activates the ROS-mediated ubiquitin-dependent proteasome system, leading to the degradation of E6/E7 oncoproteins [1].

抗癌药物141（化合物AE）（0.1 μM；24小时处理）显著降低HeLa细胞中的p53和Cyclin D1蛋白水平，同时抑制PI3K、Akt和STAT3的磷酸化作用，但不影响它们的总蛋白表达[1]。抗癌药物141（0.4 μM；24小时处理）通过促进HeLa细胞内泛素-蛋白酶体系统（UPS）的活性，进而介导E6/E7蛋白的降解[1]。抗癌药物141对HeLa细胞24小时、48小时、72小时处理的IC50值依次为1.35、0.12、0.03 μM[1]。